טוען...
The development of immunoconjugates for targeted cancer therapy
Immunoconjugates are specific, highly effective, minimally toxic anticancer therapies that are beginning to show promise in the clinic. Immunoconjugates consist of three separate components: an antibody that binds to a cancer cell antigen with high specificity, an effector molecule that has a high c...
שמור ב:
| הוצא לאור ב: | Nat Rev Clin Oncol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4700536/ https://ncbi.nlm.nih.gov/pubmed/25265912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2014.159 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|